Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | Progress in the Davos Alzheimer’s Collaborative’s Global Cohort Development program

Rhoda Au, PhD, Boston University School of Medicine, Boston, MA, shares an overview of the progress made in developing a global cohort to advance our understanding of Alzheimer’s disease (AD) among diverse populations. The Davos Alzheimer’s Collaborative, launched in January 2021, is undertaking a Global Cohort Development program. The program has been establishing collaborations with existing cohorts to collect new digital phenotypic data that can be harmonized with existing cohort data. To date, 22 cohorts have been recruited from 16 different countries. Using smartphones/tablets, each cohort will record AD-related cognitive and behavioral symptoms across the disease continuum and monitor changes in these symptoms over time. The digital protocol has been carefully designed to achieve global reach that works regardless of resources and expertise available. It is hoped that one million participants can be recruited within the next five years to set right the world’s current data divide. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.


Rhoda Au reports the following disclosures: Signant Health, Biogen, Eisai, Eversana/TauRx, GSK, Merck, Novartis, NovoNordisk.